{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:16Z","timestamp":1786982116569,"version":"build-2736575974"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T00:00:00Z","timestamp":1429315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s11886-015-0582-z","type":"journal-article","created":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T23:25:06Z","timestamp":1429226706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Statin Intolerance: Diagnosis and Remedies"],"prefix":"10.1007","volume":"17","author":[{"given":"Angela","family":"Pirillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico Luigi","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,18]]},"reference":[{"key":"582_CR1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/2047487313480435","volume":"20","author":"H Naci","year":"2013","unstructured":"Naci H, Brugts JJ, Fleurence R, et al. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013;20:641\u201357.","journal-title":"Eur J Prev Cardiol"},{"key":"582_CR2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"582_CR3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","volume":"104","author":"EJ Mills","year":"2011","unstructured":"Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104:109\u201324.","journal-title":"QJM"},{"key":"582_CR4","doi-asserted-by":"crossref","first-page":"E1189","DOI":"10.1503\/cmaj.101280","volume":"183","author":"M Tonelli","year":"2011","unstructured":"Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011;183:E1189\u2013202.","journal-title":"CMAJ"},{"key":"582_CR5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/eurheartj\/ehr035","volume":"32","author":"EJ Mills","year":"2011","unstructured":"Mills EJ, O\u2019Regan C, Eyawo O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J. 2011;32:1409\u201315.","journal-title":"Eur Heart J"},{"key":"582_CR6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1600-0404.2010.01450.x","volume":"124","author":"DK Chan","year":"2011","unstructured":"Chan DK, O\u2019Rourke F, Shen Q, et al. Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurol Scand. 2011;124:188\u201395.","journal-title":"Acta Neurol Scand"},{"key":"582_CR7","first-page":"CD004816","volume":"1","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.","journal-title":"Cochrane Database Syst Rev"},{"key":"582_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","volume":"217","author":"AL Catapano","year":"2011","unstructured":"Catapano AL, Reiner Z, de Backer G, et al. ESC\/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3\u201346.","journal-title":"Atherosclerosis"},{"key":"582_CR9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clinthera.2010.02.004","volume":"32","author":"G Corrao","year":"2010","unstructured":"Corrao G, Conti V, Merlino L, et al. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther. 2010;32:300\u201310.","journal-title":"Clin Ther"},{"key":"582_CR10","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","volume":"150","author":"TR Joy","year":"2009","unstructured":"Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858\u201368.","journal-title":"Ann Intern Med"},{"key":"582_CR11","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","volume":"97","author":"M Law","year":"2006","unstructured":"Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52C\u201360.","journal-title":"Am J Cardiol"},{"key":"582_CR12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","volume":"78","author":"G Fernandez","year":"2011","unstructured":"Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393\u2013403.","journal-title":"Cleve Clin J Med"},{"key":"582_CR13","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMp1112023","volume":"365","author":"P Maningat","year":"2011","unstructured":"Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365:2250\u20131.","journal-title":"N Engl J Med"},{"key":"582_CR14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.trsl.2014.01.013","volume":"164","author":"DA Taha","year":"2014","unstructured":"Taha DA, de Moor CH, Barrett DA, et al. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Transl Res. 2014;164:85\u2013109.","journal-title":"Transl Res"},{"key":"582_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","volume":"33","author":"YS Chatzizisis","year":"2010","unstructured":"Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33:171\u201387.","journal-title":"Drug Saf"},{"key":"582_CR16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","volume":"96","author":"A Alfirevic","year":"2014","unstructured":"Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014;96:470\u20136. In this paper, the authors defined phenotypic criteria to standardize statin-induced myotoxicity phenotypes, based on a previously described consensus approach.","journal-title":"Clin Pharmacol Ther"},{"key":"582_CR17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","volume":"48","author":"P Mohassel","year":"2013","unstructured":"Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve. 2013;48:477\u201383.","journal-title":"Muscle Nerve"},{"key":"582_CR18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"key":"582_CR19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.numecd.2012.04.012","volume":"23","author":"D Rosenbaum","year":"2013","unstructured":"Rosenbaum D, Dallongeville J, Sabouret P, et al. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2013;23:871\u20135. This survey revealed the higher frequency of muscular symptoms associated with statin therapy in real life than in clinical trials.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"582_CR20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96\u2013103.","journal-title":"Circulation"},{"key":"582_CR21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2013.07.001","volume":"230","author":"KD Ballard","year":"2013","unstructured":"Ballard KD, Parker BA, Capizzi JA, et al. Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis. 2013;230:121\u20134.","journal-title":"Atherosclerosis"},{"key":"582_CR22","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","volume":"49","author":"L Marcoff","year":"2007","unstructured":"Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"582_CR23","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00018-006-6235-z","volume":"63","author":"P Kaufmann","year":"2006","unstructured":"Kaufmann P, Torok M, Zahno A, et al. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci. 2006;63:2415\u201325.","journal-title":"Cell Mol Life Sci"},{"key":"582_CR24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/taap.1995.1058","volume":"131","author":"BA Masters","year":"1995","unstructured":"Masters BA, Palmoski MJ, Flint OP, et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 1995;131:163\u201374.","journal-title":"Toxicol Appl Pharmacol"},{"key":"582_CR25","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","volume":"130","author":"RH Ho","year":"2006","unstructured":"Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130:1793\u2013806.","journal-title":"Gastroenterology"},{"key":"582_CR26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0022-3565(24)29609-9","volume":"297","author":"D Nakai","year":"2001","unstructured":"Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 2001;297:861\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"582_CR27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clinthera.2007.02.008","volume":"29","author":"M Silva","year":"2007","unstructured":"Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29:253\u201360.","journal-title":"Clin Ther"},{"key":"582_CR28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","volume":"346","author":"JA Staffa","year":"2002","unstructured":"Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539\u201340.","journal-title":"N Engl J Med"},{"key":"582_CR29","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1124\/dmd.30.12.1352","volume":"30","author":"JS Wang","year":"2002","unstructured":"Wang JS, Neuvonen M, Wen X, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002;30:1352\u20136.","journal-title":"Drug Metab Dispos"},{"key":"582_CR30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.105.007633","volume":"34","author":"BW Ogilvie","year":"2006","unstructured":"Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug\u2013drug interactions. Drug Metab Dispos. 2006;34:191\u20137.","journal-title":"Drug Metab Dispos"},{"key":"582_CR31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"M Schachter","year":"2005","unstructured":"Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117\u201325.","journal-title":"Fundam Clin Pharmacol"},{"key":"582_CR32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565\u201381.","journal-title":"Clin Pharmacol Ther"},{"key":"582_CR33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0021-9150(01)00438-5","volume":"158","author":"N Ichimaru","year":"2001","unstructured":"Ichimaru N, Takahara S, Kokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis. 2001;158:417\u201323.","journal-title":"Atherosclerosis"},{"key":"582_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jacl.2013.10.006","volume":"8","author":"MK Ito","year":"2014","unstructured":"Ito MK, Maki KC, Brinton EA, et al. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study. J Clin Lipidol. 2014;8:69\u201376. This study showed the relevance of drug-drug interaction as a risk factor for muscle-related side effects in patients taking statins and concomitant therapies that interfere with statin metabolism.","journal-title":"J Clin Lipidol"},{"key":"582_CR35","doi-asserted-by":"crossref","first-page":"e78827","DOI":"10.1371\/journal.pone.0078827","volume":"8","author":"E Tragni","year":"2013","unstructured":"Tragni E, Casula M, Pieri V, et al. Prevalence of the prescription of potentially interacting drugs. PLoS One. 2013;8:e78827.","journal-title":"PLoS One"},{"key":"582_CR36","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","volume":"8","author":"KA Kellick","year":"2014","unstructured":"Kellick KA, Bottorff M, Toth PP. A clinician\u2019s guide to statin drug\u2013drug interactions. J Clin Lipidol. 2014;8:S30\u201346.","journal-title":"J Clin Lipidol"},{"key":"582_CR37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","volume":"78","author":"E Lee","year":"2005","unstructured":"Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"582_CR38","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","volume":"99","author":"JK Liao","year":"2007","unstructured":"Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410\u20134.","journal-title":"Am J Cardiol"},{"key":"582_CR39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","volume":"24","author":"M Needham","year":"2014","unstructured":"Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord. 2014;24:4\u201315.","journal-title":"Neuromuscul Disord"},{"key":"582_CR40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N Engl J Med. 2008;359:789\u201399.","journal-title":"N Engl J Med"},{"key":"582_CR41","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","volume":"16","author":"MK Pasanen","year":"2006","unstructured":"Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16:873\u20139.","journal-title":"Pharmacogenet Genomics"},{"key":"582_CR42","doi-asserted-by":"crossref","unstructured":"Stewart A. SLCO1B1 Polymorphisms and statin-induced myopathy. PLoS Curr 2013;5. doi: 10.1371\/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203","DOI":"10.1371\/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203"},{"key":"582_CR43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/tpj.2010.92","volume":"12","author":"LR Brunham","year":"2012","unstructured":"Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012;12:233\u20137.","journal-title":"Pharmacogenomics J"},{"key":"582_CR44","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ahj.2013.01.025","volume":"165","author":"JS Danik","year":"2013","unstructured":"Danik JS, Chasman DI, MacFadyen JG, et al. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J. 2013;165:1008\u201314.","journal-title":"Am Heart J"},{"key":"582_CR45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","volume":"96","author":"LB Ramsey","year":"2014","unstructured":"Ramsey LB, Johnson SG, Caudle KE, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96:423\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"582_CR46","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","volume":"11","author":"D Wang","year":"2011","unstructured":"Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274\u201386.","journal-title":"Pharmacogenomics J"},{"key":"582_CR47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/FPC.0b013e32834c6edb","volume":"21","author":"L Elens","year":"2011","unstructured":"Elens L, Becker ML, Haufroid V, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics. 2011;21:861\u20136.","journal-title":"Pharmacogenet Genomics"},{"key":"582_CR48","doi-asserted-by":"crossref","unstructured":"Ragia G, Kolovou V, Tavridou A, et al. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. Drug Metabol Drug Interact 2015; in press. doi: 10.1515\/dmdi-2014-0021","DOI":"10.1515\/dmdi-2014-0021"},{"key":"582_CR49","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2217\/pgs.14.90","volume":"15","author":"M Leusink","year":"2014","unstructured":"Leusink M, de Keyser CE, Onland-Moret NC, et al. No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction. Pharmacogenomics. 2014;15:1471\u20137.","journal-title":"Pharmacogenomics"},{"key":"582_CR50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/03007995.2013.858619","volume":"30","author":"J Li","year":"2014","unstructured":"Li J, Wang X, Zhang Z, et al. Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia. Curr Med Res Opin. 2014;30:223\u20138.","journal-title":"Curr Med Res Opin"},{"key":"582_CR51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","volume":"34","author":"GD Vladutiu","year":"2006","unstructured":"Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34:153\u201362.","journal-title":"Muscle Nerve"},{"key":"582_CR52","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526\u201334.","journal-title":"Ann Intern Med"},{"key":"582_CR53","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","volume":"166","author":"WM Mampuya","year":"2013","unstructured":"Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597\u2013603.","journal-title":"Am Heart J"},{"key":"582_CR54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DMSO.S11244","volume":"4","author":"M Arca","year":"2011","unstructured":"Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes. 2011;4:155\u201366.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"582_CR55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.clinthera.2006.06.004","volume":"28","author":"CJ Glueck","year":"2006","unstructured":"Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10 mg\/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther. 2006;28:933\u201342.","journal-title":"Clin Ther"},{"key":"582_CR56","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25:2822\u201335.","journal-title":"Clin Ther"},{"key":"582_CR57","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2008.09.095","volume":"103","author":"JF Ruisinger","year":"2009","unstructured":"Ruisinger JF, Backes JM, Gibson CA, et al. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol. 2009;103:393\u20134.","journal-title":"Am J Cardiol"},{"key":"582_CR58","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacl.2011.11.002","volume":"6","author":"JM Backes","year":"2011","unstructured":"Backes JM, Gibson CA, Ruisinger JF, et al. The high-dose rosuvastatin once weekly study (the HD-ROWS). J Clin Lipidol. 2011;6:362\u20137.","journal-title":"J Clin Lipidol"},{"key":"582_CR59","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","volume":"42","author":"JM Backes","year":"2008","unstructured":"Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008;42:341\u20136.","journal-title":"Ann Pharmacother"},{"key":"582_CR60","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2007.09.096","volume":"101","author":"VG Athyros","year":"2008","unstructured":"Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol. 2008;101:483\u20135.","journal-title":"Am J Cardiol"},{"key":"582_CR61","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2012.02.006","volume":"23","author":"A Elis","year":"2012","unstructured":"Elis A, Lishner M. Non-every day statin administration\u2014a literature review. Eur J Intern Med. 2012;23:474\u20138.","journal-title":"Eur J Intern Med"},{"key":"582_CR62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.amjmed.2012.08.007","volume":"126","author":"FI Marcus","year":"2013","unstructured":"Marcus FI, Baumgarten AJ, Fritz WL, et al. Alternate-day dosing with statins. Am J Med. 2013;126:99\u2013104.","journal-title":"Am J Med"},{"key":"582_CR63","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","volume":"265","author":"A Pandor","year":"2009","unstructured":"Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265:568\u201380.","journal-title":"J Intern Med"},{"key":"582_CR64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1476-511X-8-56","volume":"8","author":"SS Kumar","year":"2009","unstructured":"Kumar SS, Lahey KA, Day A, et al. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis. 2009;8:56.","journal-title":"Lipids Health Dis"},{"key":"582_CR65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2710.2008.01004.x","volume":"34","author":"G Derosa","year":"2009","unstructured":"Derosa G, D\u2019Angelo A, Franzetti IG, et al. Efficacy and safety of ezetimibe\/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J Clin Pharm Ther. 2009;34:267\u201376.","journal-title":"J Clin Pharm Ther"},{"key":"582_CR66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","volume":"168","author":"MA Blazing","year":"2014","unstructured":"Blazing MA, Giugliano RP, Cannon CP, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014;168:205\u201312.","journal-title":"Am Heart J"},{"key":"582_CR67","unstructured":"Cannon CP on behalf of the IMPROVE-IT Investigators. IMPROVE-IT Trial: a comparison of ezetimibe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Presented at the American Heart Association Scientific Session. Chicago, United States of America; November 15\u201319, 2014."},{"key":"582_CR68","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146\u201357.","journal-title":"Eur Heart J"},{"key":"582_CR69","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","volume":"55","author":"F Akdim","year":"2010","unstructured":"Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55:1611\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"582_CR70","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","volume":"105","author":"F Akdim","year":"2010","unstructured":"Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413\u20139.","journal-title":"Am J Cardiol"},{"key":"582_CR71","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","volume":"114","author":"JJ Kastelein","year":"2006","unstructured":"Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114:1729\u201335.","journal-title":"Circulation"},{"key":"582_CR72","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","volume":"7","author":"MP McGowan","year":"2012","unstructured":"McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.","journal-title":"PLoS One"},{"key":"582_CR73","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998\u20131006.","journal-title":"Lancet"},{"key":"582_CR74","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","volume":"126","author":"EA Stein","year":"2012","unstructured":"Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283\u201392.","journal-title":"Circulation"},{"key":"582_CR75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/0003088-200948010-00003","volume":"48","author":"RZ Yu","year":"2009","unstructured":"Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2\u2032-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet. 2009;48:39\u201350.","journal-title":"Clin Pharmacokinet"},{"key":"582_CR76","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","volume":"35","author":"A Sahebkar","year":"2013","unstructured":"Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35:1082\u201398.","journal-title":"Clin Ther"},{"key":"582_CR77","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jacl.2013.02.004","volume":"7","author":"PP Toth","year":"2013","unstructured":"Toth PP. Emerging LDL, therapies: mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia. J Clin Lipidol. 2013;7:S6\u201310.","journal-title":"J Clin Lipidol"},{"key":"582_CR78","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","volume":"33","author":"ME Visser","year":"2012","unstructured":"Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33:1142\u20139.","journal-title":"Eur Heart J"},{"key":"582_CR79","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129:1022\u201332. This review describes 2 drugs that reduce LDL-C independently of LDLR, and thus effective in familial hypercholesterolemic patients who are at higher cardiovascular risk.","journal-title":"Circulation"},{"key":"582_CR80","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","volume":"5","author":"FF Samaha","year":"2008","unstructured":"Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5:497\u2013505.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"582_CR81","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","volume":"356","author":"M Cuchel","year":"2007","unstructured":"Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148\u201356.","journal-title":"N Engl J Med"},{"key":"582_CR82","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40\u20136.","journal-title":"Lancet"},{"key":"582_CR83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","volume":"228","author":"AL Catapano","year":"2013","unstructured":"Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228:18\u201328.","journal-title":"Atherosclerosis"},{"key":"582_CR84","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","volume":"49","author":"HE Careskey","year":"2008","unstructured":"Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9. J Lipid Res. 2008;49:394\u20138.","journal-title":"J Lipid Res"},{"key":"582_CR85","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24:1454\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"582_CR86","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","volume":"16","author":"M Abifadel","year":"2014","unstructured":"Abifadel M, Elbitar S, el Khoury P, et al. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep. 2014;16:439.","journal-title":"Curr Atheroscler Rep"},{"key":"582_CR87","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497\u2013506.","journal-title":"JAMA"},{"key":"582_CR88","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541\u20138. This clinical trial identified evolocumab as a promising therapy for statin-intolerant patients at high cardiovascular risk.","journal-title":"J Am Coll Cardiol"},{"key":"582_CR89","doi-asserted-by":"crossref","first-page":"e98611","DOI":"10.1371\/journal.pone.0098611","volume":"9","author":"Y Li","year":"2014","unstructured":"Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One. 2014;9:e98611.","journal-title":"PLoS One"},{"key":"582_CR90","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.amjcard.2009.10.045","volume":"105","author":"CV Venero","year":"2010","unstructured":"Venero CV, Venero JV, Wortham DC, et al. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol. 2010;105:664\u20136.","journal-title":"Am J Cardiol"},{"key":"582_CR91","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7326\/0003-4819-150-12-200906160-00006","volume":"150","author":"DJ Becker","year":"2009","unstructured":"Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830\u20139.","journal-title":"Ann Intern Med"},{"key":"582_CR92","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjcard.2009.08.672","volume":"105","author":"SC Halbert","year":"2010","unstructured":"Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105:198\u2013204.","journal-title":"Am J Cardiol"},{"key":"582_CR93","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s12325-011-0082-5","volume":"28","author":"G Marazzi","year":"2011","unstructured":"Marazzi G, Cacciotti L, Pelliccia F, et al. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther. 2011;28:1105\u201313.","journal-title":"Adv Ther"},{"key":"582_CR94","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm1135","volume":"10","author":"W Kong","year":"2004","unstructured":"Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344\u201351.","journal-title":"Nat Med"},{"key":"582_CR95","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","volume":"201","author":"J Cameron","year":"2008","unstructured":"Cameron J, Ranheim T, Kulseth MA, et al. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008;201:266\u201373.","journal-title":"Atherosclerosis"},{"key":"582_CR96","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0033-1348620","volume":"79","author":"H Dong","year":"2013","unstructured":"Dong H, Zhao Y, Zhao L, et al. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013;79:437\u201346.","journal-title":"Planta Med"},{"key":"582_CR97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1476-511X-11-123","volume":"11","author":"L Pisciotta","year":"2012","unstructured":"Pisciotta L, Bellocchio A, Bertolini S. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis. 2012;11:123.","journal-title":"Lipids Health Dis"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-015-0582-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-015-0582-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-015-0582-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T13:23:01Z","timestamp":1747920181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-015-0582-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,18]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s11886-015-0582-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,18]]},"article-number":"27"}}